This week’s stories: 

Sinclair’s This Is the Test: Are we about to see age reversal in humans? 

At the World Governments Summit 2026 in Dubai, Harvard geneticist David Sinclair told world leaders that ageing could soon be reversible and said the first human clinical trials of epigenetic reprogramming therapies are moving forward. The core idea is that ageing is partly an information problem, how cells read DNA, not just cumulative damage, and that partial reprogramming could restore youthful function without turning tissues into tumors. Dave frames this as a rare binary moment for longevity: either early, localized human trials (starting with tightly controlled tissue targets like the eye) show meaningful functional rejuvenation with acceptable safety, or the field has to recalibrate fast. Either way, the next couple of years will heavily influence where money, regulators, and serious researchers place their bets.   

• Sources: 

– World Governments Summit: https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026   

– NAD / Life Biosciences coverage: https://www.nad.com/news/fda-greenlights-life-biosciences-human-study-setting-up-pivotal-test-for-aging-theory-from-harvards-david-sinclair   

AlphaFold 4 in a locked box: DeepMind’s private AI drug design engine 

Isomorphic Labs, DeepMind’s drug discovery company, unveiled a proprietary drug design engine that outside scientists are comparing to an AlphaFold 4 moment, but for designing drugs, not just predicting structures. The big shift is that this system is closed: no public weights, no open database, and access appears to flow through partnerships with pharma companies. Dave breaks down why that matters for the longevity world: if AI makes early discovery cheaper and faster, we might see more serious shots on ageing targets over the next decade, but a closed model can also mean less transparency, bigger IP moats, and no guarantee that faster discovery leads to cheaper drugs.   

• Sources: 

– Nature: https://www.nature.com/articles/d41586-026-00365-7   

– Isomorphic Labs: https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier   

<